AccScience Publishing / GPD / Volume 3 / Issue 4 / DOI: 10.36922/gpd.4269
Submit to GPD
Cite this article
9
Download
177
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Application of multiple inflammatory markers combined with PIVKA-II in differential diagnosis of AFP-NHCC

Wen-Tan Hu1† ,  Xin-Ying Ji2,3† ,  Zhi-Liang Jiang4,5 ,  Yi Liu4,6 ,  Huang-Yin Luo5 ,  De-Xin Zhang1 ,  Yi-Bin Lu1 ,  Ning Luo1*
Show Less
1 Xinyang Central Hospital, Xinyang, Henan, China
2 Center for Molecular Medicine, Faculty of Basic Medical Subjects, Shu-Qing Medical College of Zhengzhou, Erqi District, Zhengzhou, Henan, China
3 Department of Nuclear Medicine, Henan International Joint Laboratory for Nuclear Protein Regulation, the First Affiliated Hospital, Henan University College of Medicine, Kaifeng, Henan, China
4 Kaifeng Municipal Key Laboratory for Infection and Biosafety, Henan International Joint Laboratory of Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University College of Medicine, Kaifeng, Henan, China
5 School of Clinical Medicine, Henan University, Kaifeng, Henan, China
6 School of Stomatology, Henan University, Kaifeng, Henan, China
GPD 2024, 3(4), 4269 https://doi.org/10.36922/gpd.4269
Submitted: 17 July 2024 | Accepted: 4 November 2024 | Published: 28 November 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Alpha-fetoprotein (AFP) is a proven blood biomarker widely used in clinical detection of liver cancer, and its concentration increases immediately after liver injury, with high diagnostic specificity and low sensitivity. However, in patients with AFP-negative hepatocellular carcinoma (AFP-NHCC), also known as small liver cancer, their early stage of AFP expression is usually low or close to the normal range. Compared with AFP-positive HCC, AFP-NHCC is more likely to be subjected to missed diagnosis due to solely dependence on the measurement of blood AFP. Therefore, it is necessary to find a reliable, effective, and economical detection method for the early diagnosis of AFP-NHCC. PIVKA-II is closely related to the occurrence, development, invasion, and metastasis of liver cancer, and is also a new hematological marker widely used in the diagnosis of liver cancer in recent years. PIVKA-II effectively makes up for the limitation of negative AFP. 63.2% – 76.3% of patients with negative AFP showed positive PIVKA-II, and if only PIVKA-II detection was relied on, there would still be missed diagnosis in early patients with AFP-NHCC. In this retrospective study, we selected several commonly used inflammatory indicators to explore the diagnostic efficacy of PIVKA-II, an abnormal form of prothrombin, combined with inflammatory indicators in patients with early-stage AFP-NHCC and analyzed the relationship between some clinical features and hematological indicators in patients with AFP-NHCC. Serum levels of high-sensitivity C-reactive protein (hs-CRP), prealbumin (PA), neutrophil/lymphocyte ratio (NLR), and PIVKA-II were compared among three groups (AFP-NHCC group, benign lesion group, and healthy subjects). The diagnostic efficacy of PIVKA-II alone for AFP-NHCC and the diagnostic efficacy of three inflammatory indicators combined with PIVKA-II for AFP-NHCC were calculated, and their diagnostic specificity and sensitivity were compared. Compared with the other two groups, the AFP-NHCC group showed significant changes in three inflammatory markers and PIVKA-II, which may be related to the inflammatory progression of the tumor. Therefore, we recommend the establishment of a laboratory-based detection approach for diagnosing early-stage AFP-NHCC by combining PIVKA-II with inflammatory indicators hs-CRP, PA, and NLR, to facilitate diagnosis, treatment, and prognosis of AFP-NHCC.

Keywords
Alpha-fetoprotein-negative hepatocellular carcinoma
Prealbumin
PIVKA-II
High-sensitivity C-reactive protein
Funding
This work was supported by the National Natural Science Foundation of China (Grant Nos. 31902287 and 81670988), the Kaifeng Science and Technology Development Plan (Project No. 2203008), and the Cultivation Project for Innovation Team in Teachers’ Teaching Proficiency by Zhengzhou Shu-Qing Medical College (No. 2024jxcxtd01).
Conflict of interest
Xin-Ying Ji is an Editorial Board Member of this journal but was not in any way involved in the editorial and peer-review process conducted for this paper, directly or indirectly. Separately, other authors declared that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends. 2022;16(1):20-30. doi: 10.5582/bst.2022.01061

 

  1. Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029-2041. doi: 10.1111/liv.15251

 

  1. Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7(3):308-319. doi: 10.1016/j.gendis.2020.01.014

 

  1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450-1462. doi: 10.1056/NEJMra1713263

 

  1. Mao M, Wang X, Song Y, et al. Novel prognostic scores based on plasma prothrombin time and fibrinogen levels in patients with AFP-negative hepatocellular carcinoma. Cancer Control. 2020;27(1):1073274820915520. doi: 10.1177/1073274820915520

 

  1. Li J, Wang Q, Yan Y, et al. Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection. Front Oncol. 2024;14:1414083. doi: 10.3389/fonc.2024.1414083

 

  1. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology. 2018;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064

 

  1. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World Gastroenterol. 2017;23(18):3228-3239. doi: 10.3748/wjg.v23.i18.3228

 

  1. Nagel T, Klaus F, Ibanez IG, Wege H, Lohse A, Meyer B. Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis. Anal Bioanal Chem. 2018;410(30):7965-7977. doi: 10.1007/s00216-018-1418-7

 

  1. Wang ZX, Jiang CP, Cao Y, Zhang G, Chen WB, Ding YT. Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14(2):178-185. doi: 10.1016/s1499-3872(15)60353-8

 

  1. Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019;19(1):841. doi: 10.1186/s12885-019-6011-8

 

  1. Sylman JL, Mitrugno A, Atallah M, et al. The predictive value of inflammation-related peripheral blood measurements in cancer staging and prognosis. Front Oncol. 2018;8:78. doi: 10.3389/fonc.2018.00078

 

  1. Kumar A, Jat KR, Sankar J, Lakshmy R, Lodha R, Kabra SK. Role of high-sensitivity C-reactive protein (hs-CRP) in assessment of asthma control in children. J Asthma. 2023;60(7):1466-1473. doi: 10.1080/02770903.2022.2155187

 

  1. Yin J, Wang L, Jin T, et al. A cell wall-localized NLR confers resistance to Soybean mosaic virus by recognizing viral-encoded cylindrical inclusion protein. Mol Plant. 2021;14(11):1881-1900. doi: 10.1016/j.molp.2021.07.013

 

  1. Payancé A, Dioguardi Burgio M, Peoc’h K, et al. Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2020;32(10):1364-1372. doi: 10.1097/meg.0000000000001652

 

  1. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A glasgow inflammation outcome study. Eur J Cancer. 2011;47(17):2633-2641. doi: 10.1016/j.ejca.2011.03.028

 

  1. Najjar M, Agrawal S, Emond JC, Halazun KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:17-28. doi: 10.2147/jhc.S86792

 

  1. Zenga J, Awan MJ, Frei A, et al. Chronic stress promotes an immunologic inflammatory state and head and neck cancer growth in a humanized murine model. Head Neck. 2022;44(6):1324-1334. doi: 10.1002/hed.27028

 

  1. Qiao W, Leng F, Liu T, et al. Prognostic value of prealbumin in liver cancer: A systematic review and meta-analysis. Nutr Cancer. 2020;72(6):909-916. doi: 10.1080/01635581.2019.1661501

 

  1. Chiang HC, Lin MY, Lin FC, et al. Transferrin and prealbumin identify esophageal cancer patients with malnutrition and poor prognosis in patients with normal albuminemia: A cohort study. Nutr Cancer. 2022;74(10):3546-3555. doi: 10.1080/01635581.2022.2079687

 

  1. Casadei Gardini A, Foschi FG, Conti F, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis. 2019;51(5):681-688. doi: 10.1016/j.dld.2018.09.016

 

  1. Moon G, Noh H, Cho IJ, Lee JI, Han A. Prediction of late recurrence in patients with breast cancer: Elevated Neutrophil to Lymphocyte Ratio (NLR) at 5 years after diagnosis and late recurrence. Breast Cancer. 2020;27(1):54-61. doi: 10.1007/s12282-019-00994-z

 

  1. Qian L, Li C, Luo Y, Meng S. Research progress of AFP in the diagnosis and therapy of hepatocellular carcinoma. Sheng Wu Gong Cheng Xue Bao = Chin J Biotechnol. 2021;37(9):3042-3060. doi: 10.13345/j.cjb.210235

 

  1. Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020;10:1316. doi: 10.3389/fonc.2020.01316

 

  1. Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023;79(2):538-551. doi: 10.1016/j.jhep.2023.02.033

 

  1. Yu C, Sun C. Diagnostic value of multislice spiral computed tomography combined with serum AFP, TSGF, and GP73 assay in the diagnosis of primary liver cancer. Evid Based Complement Alternat Med. 2022;2022:6581127. doi: 10.1155/2022/6581127

 

  1. Zhou J, Chen L, Chen L, Zhang Y, Yuan Y. Emerging role of nanoparticles in the diagnostic imaging of gastrointestinal cancer. Semin Cancer Biol. 2022;86(Pt 2):580-594. doi: 10.1016/j.semcancer.2022.04.009

 

  1. Yu H. Editorial comment: Thermal ablation plus systemic chemotherapy in colorectal cancer liver oligometastases-the optimal sequence and timing. AJR Am J Roentgenol. 2023;220(6):900. doi: 10.2214/ajr.22.28846

 

  1. Fotiadis N, De Paepe KN, Bonne L, et al. Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: Diagnostic yield, complications and seeding risk. Eur Radiol. 2020;30(12):6702-6708. doi: 10.1007/s00330-020-07038-7

 

  1. Yin L, Chen L, Qi Z, et al. Gene expression-based immune infiltration analyses of liver cancer and their associations with survival outcomes. Cancer Genet. 2021;254-255:75-81. doi: 10.1016/j.cancergen.2021.02.001

 

  1. Yu H, He J, Liu W, et al. The transcriptional coactivator, ALL1-fused gene from chromosome 9, simultaneously sustains hypoxia tolerance and metabolic advantages in liver cancer. Hepatology. 2021;74(4):1952-1970. doi: 10.1002/hep.31870

 

  1. Nazzal M, Sur S, Steele R, et al. Establishment of a patient-derived xenograft tumor from hepatitis C-Associated liver cancer and evaluation of imatinib treatment efficacy. Hepatology. 2020;72(2):379-388. doi: 10.1002/hep.31298

 

  1. Abouzed TK, Althobaiti F, Omran AF, et al. The chemoprevention of spirulina platensis and garlic against diethylnitrosamine induced liver cancer in rats via amelioration of inflammatory cytokines expression and oxidative stress. Toxicol Res (Camb). 2022;11(1):22-31. doi: 10.1093/toxres/tfab118

 

  1. Sugimoto A, Yoshizawa A, Yoshida A, et al. Retroperitoneal malignant extra-gastrointestinal neuroectodermal tumor with EWSR1:CREM fusion and IL-6-related systemic inflammatory symptoms: A case report. Virchows Arch. 2023;482(5):911-915. doi: 10.1007/s00428-022-03442-0

 

  1. McFarland DC, Doherty M, Atkinson TM, et al. Cancer-related inflammation and depressive symptoms: Systematic review and meta-analysis. Cancer. 2022;128(13):2504-2519. doi: 10.1002/cncr.34193

 

  1. Pratt HG, Steinberger KJ, Mihalik NE, et al. Macrophage and neutrophil interactions in the pancreatic tumor microenvironment drive the pathogenesis of pancreatic cancer. Cancers (Basel). 2021;14(1):194. doi: 10.3390/cancers14010194

 

  1. Schauer T, Mazzoni AS, Henriksson A, et al. Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment. Endocr Relat Cancer. 2021;28(3):191-201. doi: 10.1530/erc-20-0507

 

  1. Patten DA, Wilkinson AL, O’Keeffe A, Shetty S. Scavenger receptors: Novel roles in the pathogenesis of liver inflammation and cancer. Semin Liver Dis. 2022;42(1):61-76. doi: 10.1055/s-0041-1733876

 

  1. Bishayee A. The role of inflammation and liver cancer. Adv Exp Med Biol. 2014;816:401-435. doi: 10.1007/978-3-0348-0837-8_16

 

  1. Lee FY, Lee SD, Tsai YT, Wu JC, Lai KH, Lo KJ. Serum C-reactive protein as a serum marker for the diagnosis of hepatocellular carcinoma. Cancer. 1989;63(8):1567-1571. doi: 10.1002/1097-0142(19890415)63:8<1567:aid-cncr2820 630820>3.0.co;2-j

 

  1. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32(8):1757-1762. doi: 10.1007/s00268-008-9552-6

 

  1. Wang Y, Attar BM, Fuentes HE, Jaiswal P, Tafur AJ. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. J Gastrointest Oncol. 2017;8(6):1065-1071. doi: 10.21037/jgo.2017.09.06

 

  1. Xu ZG, Ye CJ, Liu LX, et al. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: A systematic review and meta-analysis. Biomark Med. 2018;12(2):189-199. doi: 10.2217/bmm-2017-0307

 

  1. Vucur M, Ghallab A, Schneider AT, et al. Sublethal necroptosis signaling promotes inflammation and liver cancer. Immunity. 2023;56(7):1578-1595.e8. doi: 10.1016/j.immuni.2023.05.017

 

  1. Wang H, Zhang B, Li R, et al. KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration. Hepatology. 2022;76(4):967-981. doi: 10.1002/hep.32383

 

  1. Guo Y, Hu HT, Xu SJ, et al. Correlation of serum chemokine ligand 14 with barcelona clinic liver cancer stage, lymphocyte profile, and response to transarterial chemoembolization in patients with hepatocellular carcinoma. J Vasc Intervr Radiol. 2023;34(6):991-998. doi: 10.1016/j.jvir.2023.01.032

 

  1. Kastle S, Stechele MR, Richter L, et al. Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer. J Cancer Res Clin Oncol. 2023;149(12):9777-9786. doi: 10.1007/s00432-023-04875-z

 

  1. Suner A, Carr BI, Akkiz H, et al. C-reactive protein and platelet-lymphocyte ratio as potential tumor markers in low-alpha-fetoprotein hepatocellular carcinoma. Oncology. 2019;96(1):25-32. doi: 10.1159/000492473

 

  1. Li K, Xu Y, Hu Y, Liu Y, Chen X, Zhou Y. Effect of enteral immunonutrition on immune, inflammatory markers and nutritional status in gastric cancer patients undergoing gastrectomy: A randomized double-blinded controlled trial. J Invest Surg. 2020;33(10):950-959. doi: 10.1080/08941939.2019.1569736

 

  1. Milana F, Polidoro MA, Soldani C, et al. Unveiling the prognostic role of blood inflammatory indexes in a retrospective cohort of patients undergoing liver resection for intrahepatic cholangiocarcinoma. Int J Surg. 2024;110(11):7088-96. doi: 10.1097/JS9.0000000000001924

 

  1. Choi Y, Kim JW, Nam KH, et al. Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer. 2017;20(4):602-611. doi: 10.1007/s10120-016-0642-0

 

  1. Degasperi E, Perbellini R, D’Ambrosio R, et al. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2022;55(3):350-359. doi: 10.1111/apt.16685

 

  1. Akuta N, Kawamura Y, Suzuki F, et al. Dynamics of circulating miR-122 predict liver cancer and mortality in japanese patients with histopathologically confirmed NAFLD and severe fibrosis stage. Oncology. 2022;100(1):31-38. doi: 10.1159/000519995

 

  1. Zhang Z, Zhang Y, Wang Y, Xu L, Xu W. Alpha-fetoprotein-L3 and golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther. 2016;9:123-139. doi: 10.2147/ott.S90732

 

  1. Zhu L, Li T, Ma X, et al. A simple noninvasive index can predict hepatocellular carcinoma in patients with chronic hepatitis B. Sci Rep. 2017;7(1):8954. doi: 10.1038/s41598-017-09358-z
Share
Back to top
Gene & Protein in Disease, Electronic ISSN: 2811-003X Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept